Edition:
United States

Aeterna Zentaris Inc (AEZS.OQ)

AEZS.OQ on NASDAQ Stock Exchange Capital Market

3.93USD
2:13pm EDT
Change (% chg)

$-0.32 (-7.53%)
Prev Close
$4.25
Open
$4.25
Day's High
$4.25
Day's Low
$3.89
Volume
84,846
Avg. Vol
53,707
52-wk High
$5.56
52-wk Low
$1.30

Latest Key Developments (Source: Significant Developments)

Aeterna Zentaris Q4 Loss Per Share $0.31
Tuesday, 26 Mar 2019 05:21pm EDT 

March 26 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL AND OPERATING RESULTS.Q4 LOSS PER SHARE $0.31.TOTAL REVENUE FOR Q4 2018 WAS $1.4 MILLION, COMPARED TO $0.2 MILLION FOR Q4 2017.AS OF DECEMBER 31, 2018, CO HAD $14.5 MILLION OF UNRESTRICTED CASH AND CASH EQUIVALENTS.  Full Article

Aeterna Zentaris Settles Dispute with Cogas Consulting LLC
Tuesday, 6 Nov 2018 08:00am EST 

Nov 6 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS INC - CO, COGAS CONSULTING LLC RESOLVED THEIR DISPUTE; BOTH COS NOW CONSIDER THEIR CONTRACTUAL RELATIONSHIP AS HAVING BEEN TERMINATED.  Full Article

Aeterna Zentaris Inc QTRLY Loss Per Share $0.16
Thursday, 9 Aug 2018 04:18pm EDT 

Aeterna Zentaris Inc ::AETERNA ZENTARIS REPORTS SECOND QUARTER 2018 FINANCIAL AND OPERATING RESULTS.AETERNA ZENTARIS INC QTRLY LOSS PER SHARE $0.16.AETERNA ZENTARIS INC QTRLY TOTAL REVENUES $168,000 VERSUS $243,000.  Full Article

Aeterna Zentaris Appoints James Clavijo As CFO
Monday, 5 Mar 2018 04:05pm EST 

March 5 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS APPOINTS JAMES CLAVIJO AS CHIEF FINANCIAL OFFICER.AETERNA ZENTARIS INC - ‍CLAVIJO JOINS AETERNA ZENTARIS FROM TRI-SOURCE PHARMA​.AETERNA ZENTARIS - ‍APPOINTMENT OF JAMES CLAVIJO AS CHIEF FINANCIAL OFFICER EFFECTIVE MARCH 5​.  Full Article

Aeterna Zentaris Provides Update On Previously Disclosed Class Action Lawsuit
Monday, 5 Mar 2018 07:45am EST 

March 5 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS PROVIDES UPDATE ON PREVIOUSLY DISCLOSED CLASS ACTION LAWSUIT.AETERNA ZENTARIS - ‍ U.S. COURT GRANTED MOTION FOR CLASS CERTIFICATION IN CLASS ACTION LAWSUIT AGAINST CO, CERTAIN OFFICERS RELATED TO MACRILEN.AETERNA ZENTARIS INC - ‍ HAS NOT RECORDED ANY LIABILITY RELATED TO LAWSUIT​.  Full Article

David Dodd And Philip Theodore Respond To Claim By Aeterna Zentaris
Thursday, 21 Dec 2017 04:01pm EST 

Dec 21 (Reuters) - Aeterna Zentaris Inc ::DAVID DODD AND PHILIP THEODORE RESPOND TO CLAIM BY AETERNA ZENTARIS.DAVID DODD - DODD, FORMER CEO OF AETERNA ZENTARIS & PHILIP THEODORE, CO'S FORMER GENERAL COUNSEL, HAVE RESPONDED TO CLAIM FILED AGAINST THEM BY CO.DAVID DODD SAYS DODD & PHILIP THEODORE HAVE BROUGHT A COUNTERCLAIM AGAINST CO & ITS CHAIR, CAROLYN EGBERT, IN AMOUNT OF $6.0 MILLION.DAVID DODD - DODD AND THEODORE HAVE BROUGHT COUNTERCLAIM AGAINST CO AND ITS CHAIR, CAROLYN EGBERT, IN AMOUNT OF $6.0 MILLION.  Full Article

Aeterna Zentaris Announces FDA Approval Of Macrilen For Diagnosis Of Adult Growth Hormone Deficiency
Wednesday, 20 Dec 2017 05:00pm EST 

Dec 20 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS ANNOUNCES FDA APPROVAL OF MACRILEN™ (MACIMORELIN) FOR DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY.AETERNA ZENTARIS - INTENDS TO MAKE MACRILEN AVAILABLE COMMERCIALLY IN UNITED STATES DURING Q1 OF 2018.  Full Article

Aeterna Zentaris Announces Departure Of Interim Chief Financial Officer
Friday, 8 Dec 2017 08:00am EST 

Dec 8 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS ANNOUNCES DEPARTURE OF INTERIM CHIEF FINANCIAL OFFICER.AETERNA ZENTARIS INC - DEPARTURE OF COMPANY'S INTERIM CHIEF FINANCIAL OFFICER, JEFFREY WHITNELL, EFFECTIVE DECEMBER 7, 2017.AETERNA ZENTARIS INC - COMMENCED A SEARCH FOR WHITNELL'S REPLACEMENT AS PRINCIPAL FINANCIAL OFFICER.  Full Article

Aeterna Zentaris’ MAA for Macrilen™ accepted by EMA
Monday, 27 Nov 2017 04:41pm EST 

Nov 27 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS’ MARKETING AUTHORIZATION APPLICATION FOR MACRILEN™ (MACIMORELIN) FOR EVALUATION OF ADULT GROWTH HORMONE DEFICIENCY ACCEPTED BY EUROPEAN MEDICINES AGENCY.AETERNA ZENTARIS INC - ‍MAA FOR USE OF MACRILEN FOR EVALUATION OF ADULT GROWTH HORMONE DEFICIENCY BEEN ACCEPTED BY EMA FOR REGULATORY REVIEW​.  Full Article

Aeterna Zentaris reports Q3 loss per share of $0.61
Wednesday, 8 Nov 2017 05:05pm EST 

Nov 8 (Reuters) - Aeterna Zentaris Inc :Aeterna Zentaris reports third quarter 2017 financial and operating results.Q3 loss per share $0.61.  Full Article